Tumor type and vascularity: Important variables in infusional brachytherapy with colloidal 32P

Nguyen, Hien; Ghanem, Ghanem; Morandini, Renato; Verbist, A; Larsimont, Denis; Fallais, Charles; Fruhling, Janos; Houtte, Paul Van

doi:10.1016/s0360-3016(97)00294-0

Cited by 13 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditional brachytherapy has not been beneficial in this situation [192], but initial reports of success have appeared with a brachytherapy method that traps the radionuclide inside a balloon that expands to conform with regional boundaries of the cavity [193,194]. Nontargeted 90 Y or 32 P colloidal or microsphere therapy has been given intratumorally or locally for a variety of solid tumors and in brain cancer with some success [195][196][197][198][199][200]. This form of non-targeted therapy is effective in reducing the size of cystic craniopharyngiomas [199][200][201][202][203], which appears to be related to destruction of the epithelial cells that line the cyst wall, replaced with a collagen layer that inhibits fluidic movement [204,205].…”

Section: Intracavitary Targetingmentioning

confidence: 99%

Use of antibodies and immunoconjugates for the therapy of more accessible cancers

Sharkey

Goldenberg

2008

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

There are currently 6 unconjugated antibodies and 3 immunoconjugates approved for use in the United States in a variety of cancers, with a considerable number of new agents in clinical testing and preclinical development. Unconjugated antibodies alone can be effective, but more often, antibodies need to be combined with chemotherapy, which enhances the efficacy of the standard treatment. Immunoconjugates tend to be more effective than their unconjugated counterparts, but their increased toxicity often restricts when and how they are used. In order to improve efficacy, a number of immunoconjugates are being examined in settings where the disease is more easily accessible, such as leukemias, or within compartments that allow easier and more direct access to the tumor, such as in the peritoneal cavity or brain, or both locally and systemically, in adjuvant situations, where the disease burden has been reduced by some other means, and with the main goal of these treatments being to kill residual disease.

show abstract

Section: Intracavitary Targetingmentioning

confidence: 99%

Use of antibodies and immunoconjugates for the therapy of more accessible cancers

Sharkey

Goldenberg

2008

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…Internal leakage to non-target tissues was divided in hematogenous or intravenous and intraductal leakage. In the majority of human [ 13 , 15 , 16 ] and animal [ 8 , 9 , 24 , 35 , 39 , 43 ] studies, some degree of intravenous leakage or shunting of particles through the capillary bed was described. After the improved retention of CCP particles with an additional injection of larger 10–90 μm MAA particles, 56 vs. 90%, respectively, and the hypothesis of a vascular blockade, vascularity became an important variable for leakage.…”

Section: Resultsmentioning

confidence: 99%

“…After the improved retention of CCP particles with an additional injection of larger 10–90 μm MAA particles, 56 vs. 90%, respectively, and the hypothesis of a vascular blockade, vascularity became an important variable for leakage. 32 P CCP 0.6–1.3 μm was injected in nude mice with human pigmented melanoma cell line (HBL) and a human squamous cell carcinoma cell line (SCC1); three to four times higher organ counting was found in SCC1 [ 39 ]. This phenomenon is probably explained by the difference in vascularity between HBL and SCC1 tumors, which contained 5.7 vs. 21.4 blood vessels/mm 2 , respectively.…”

Section: Resultsmentioning

confidence: 99%

Intratumoral treatment with radioactive beta-emitting microparticles: a systematic review

et al. 2017

View full text Add to dashboard Cite

PurposeThe purpose of this study was to review the role of radioactive microparticles (1–100 μm) for the treatment of solid tumors and provide a comprehensive overview of the feasibility, safety, and efficacy.MethodsA systematic search was performed in MEDLINE, EMBASE, and The Cochrane Library (January 2017) by combining synonyms for the determinants “tumor,” “injection,” and “radionuclide.” Data on injection technique, toxicity, tumor response, and survival were collected.ResultsThe search yielded 7271 studies, and 37 were included for analysis. Twelve studies were performed in human patients and 25 animal studies. The studies were heterogeneous in patient population, tumors, follow-up time, and treatment characteristics. The direct intratumoral injection of radioactive microparticles resulted in a response rate of 71% in a variety of tumors and uncomplicated procedures with high cumulative doses of >19,000 Gy were reported.ConclusionThe large variety of particles, techniques, and treated tumors in the studies provided an important insight into issues concerning efficacy, safety, particle and isotope choice, and other concepts for future research. Animal studies showed efficacy and a dose response. Most studies in humans concluded that intratumoral treatment with radioactive beta-emitting microparticles is relatively safe and effective. Conflicting evidence about safety and efficacy might be explained by the considerable variation in the treatment characteristics. Larger particles had a better retention which resulted in higher anti-tumor effect. Leakage seems to follow the path of least resistance depending on anatomical structures. Subsequently, a grid-like injection procedure with small volume depots is advised over a single large infusion. Controlled image-guided treatment is necessary because inadequate local delivery and inhomogeneous dose distribution result in reduced treatment efficacy and in potential complications.

show abstract

“…Therefore, BS imaging of P-32 after the RE of the hepatic tumors can be reflective of vascularized and viable tumoral tissues [33]. …”

Section: Discussionmentioning

confidence: 99%

Technical Considerations of Phosphorous-32 Bremsstrahlung SPECT Imaging after Radioembolization of Hepatic Tumors: A Clinical Assessment with a Review of Imaging Parameters

Pirayesh

Amoui

Akhlaghpoor

et al. 2014

Radiology Research and Practice

View full text Add to dashboard Cite

Background. Bremsstrahlung (BS) imaging during radioembolization (RE) confirms the deposition of radiotracer in hepatic/extrahepatic tumors. The aim of this study is to demonstrate 32P images and to optimize the imaging parameters. Materials and Methods. Thirty-nine patients with variable types of hepatic tumors, treated with the intra-arterial injection of 32P, were included. All patients underwent BS SPECT imaging 24–72 h after tracer administration, using low energy high resolution (LEHR) (18 patients) or medium energy general purpose (MEGP) (21 patients) collimators. A grading scale from 1 to 4 was used to express the compatibility of the 32P images with those obtained from CT/MRI. Results. Although the image quality obtained with the MEGP collimator was visually and quantitatively better than with the LEHR (76% concordance score versus 71%, resp.), there was no statistically significant difference between them. Conclusion. The MEGP collimator is the first choice for BS SPECT imaging. However, if the collimator change is time consuming (as in a busy center) or an MEGP collimator is not available, the LEHR collimator could be practical with acceptable images, especially in a SPECT study. In addition, BS imaging is a useful method to confirm the proper distribution of radiotherapeutic agents and has good correlation with anatomical findings.

show abstract

Tumor type and vascularity: Important variables in infusional brachytherapy with colloidal 32P

Cited by 13 publications

References 12 publications

Use of antibodies and immunoconjugates for the therapy of more accessible cancers

Use of antibodies and immunoconjugates for the therapy of more accessible cancers

Intratumoral treatment with radioactive beta-emitting microparticles: a systematic review

Technical Considerations of Phosphorous-32 Bremsstrahlung SPECT Imaging after Radioembolization of Hepatic Tumors: A Clinical Assessment with a Review of Imaging Parameters

Contact Info

Product

Resources

About